B700, an albumin-like melanoma-specific antigen, is a vitamin D binding protein

Farzaneh, Nushkin K.; Walden, Thomas L.; Hearing, Vincent J.; Gersten, Douglas M.

doi:10.1016/0277-5379(91)90316-6

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A long list of promising melanoma antigens has been cloned, all carrying the potential ofbeing tumour immunogens (Demetrick et al 1992;Farzaneh et al 1991 ;Wollina et al 1991). The best characterised is MAGEI expressed in 40% ofmelanomas, presented by HLA-Al and located on the X chromosome (Xq27-qter) (Carrel and Johnson, 1993;Oaks et al 1994;Van Der Bruggen, 1991).…”

Section: Soluble (Protein/peptide) Vaccinesmentioning

confidence: 99%

Vaccine Design

1997

View full text Add to dashboard Cite

Aseries presenting the results of aetlvities sponsored by the NA TO Seienee Committee, whieh aims at the dissemination of advaneed seientlflc and technologleal knowledge, with a vlew to strengthenlng links between seientific communities. The series is publlshed by an International board of publlshers in conjunctlon with the NATO Sclentific Affairs Division A Llfe Sclences B Physlcs All rights reservedNo part 01 thls book may be reproduced, stored in a retrleval syst~m, or transmitted in any lorm or by any means, electronlc, mechanlcal, photocopylng, mlcrolilming. recording, or otherwlse, wlthout written perm Iss Ion lrom the Publlsher ISBN 978-1-4899-0064-7 ISBN 978-1-4899-0062-3 (eBook) PREFACEDuring the last decade or so vaccine development has been facilitated by rapid advances in the molecular and cell biology ofthe immune system. This has laid the foundations of a new generation of vaccines exemplified by subunit vaccines produced through gene cloning and by synthetic peptides mimicking small regions ofproteins on the outer coat ofviruses. However, as subunit and peptide vaccines are only weakly or non-immunogenic, there is areal need for strategies to improve their potency.This book contains the proceedings of the 5th NATO Advanced Studies Institute (ASI), "Vaccine Design: The Role of Cytokine Networks," held at Cape Sounion Beach, Greece, during 24 June-5 July 1996 and deals in depth with the role ofbasic immunology in the regulation of immunity and vaccine design. Special emphasis is given to the use of cytokines in conjuction with vaccines with the aim ofimproving their potency or the use ofvaccines designed to improve cytokine production.

show abstract

Section: Soluble (Protein/peptide) Vaccinesmentioning

confidence: 99%

Vaccine Design

1997

View full text Add to dashboard Cite

show abstract

“…Two functional attributes of serum albumin which we have studied have been conserved in B700. Albumin's weak enzymatic activity, which interconverts prostaglandins (Farzaneh et al, 1990), and serum albumin's capacity to bind vitamin D compounds (Farzaneh et al, 1991a) are shared by B700.…”

Section: Introductionmentioning

confidence: 99%

Proteinuria of B700, a 67 kD Albumin‐like Melanoma‐Specific Antigen

Walden

Farzaneh

Hearing

et al. 1992

Pigment Cell Research

Self Cite

View full text Add to dashboard Cite

B700 is a murine melanoma antigen that is closely related to, but distinct from, serum albumin. The present study examined the metabolic fate and anatomic distribution of radioiodinated B700 and mouse serum albumin (MSA) administered s.c. to mice. In blood, both proteins were associated with the plasma fraction where the halflife of B700, a glycoprotein, was 0.5 days, compared to 2.7 days for MSA. Of particular interest was the observation that B700, a 67 kD anionic protein, was excreted primarily in urine. The selective B700-proteinuria did not alter urinary volumes or produce hematuria or edema. SDS-polyacrylamide gel electrophoresis and western blot analysis using the H-2-3-3 B700-specific monoclonal antibody revealed that B700 proteinuria occurred in B-16 murine melanoma bearing animals but not in control mice. These studies demonstrate that the tumor-bearing host readily distinguishes between very similar normal protein (MSA) and tumor-associated antigen (B700) molecules and processes them differently.

show abstract

Active Immunotherapy for Solid Tumours

Maraveyas

Dalgleish

1997

Vaccine Design

View full text Add to dashboard Cite

B700, an albumin-like melanoma-specific antigen, is a vitamin D binding protein

Cited by 5 publications

References 18 publications

Vaccine Design

Vaccine Design

Proteinuria of B700, a 67 kD Albumin‐like Melanoma‐Specific Antigen

Active Immunotherapy for Solid Tumours

Contact Info

Product

Resources

About